Avacta Group Plc enters into a partnership and license agreement with LG Chem Life Sciences

  • Avacta Group Plc (AVCT) has released an update on the Affimer® therapeutics development partnership and license agreement.
  • The company to develop Affimer® therapeutics in various disease areas has collaborated with LG Chem Life Sciences and has also entered into a license agreement.
  • The company has effectively produced a large number of Affimer proteins that bind to the first drug target nominated by LG Chem Life Sciences, which has now expanded the collaboration by nominating the second and third drug targets.
  • The company is starting the discovery programmes for Affimer binders to those new targets.